GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » PB Ratio

Corestemchemon (XKRX:166480) PB Ratio : 3.62 (As of Mar. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Corestemchemon PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-02), Corestemchemon's share price is ₩3590.00. Corestemchemon's Book Value per Share for the quarter that ended in Sep. 2024 was ₩990.95. Hence, Corestemchemon's PB Ratio of today is 3.62.

The historical rank and industry rank for Corestemchemon's PB Ratio or its related term are showing as below:

XKRX:166480' s PB Ratio Range Over the Past 10 Years
Min: 1.67   Med: 4.46   Max: 22.66
Current: 3.62

During the past 10 years, Corestemchemon's highest PB Ratio was 22.66. The lowest was 1.67. And the median was 4.46.

XKRX:166480's PB Ratio is ranked worse than
67% of 1285 companies
in the Biotechnology industry
Industry Median: 2.4 vs XKRX:166480: 3.62

During the past 12 months, Corestemchemon's average Book Value Per Share Growth Rate was -21.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -23.90% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Corestemchemon was 78.50% per year. The lowest was -29.60% per year. And the median was -14.30% per year.

Back to Basics: PB Ratio


Corestemchemon PB Ratio Historical Data

The historical data trend for Corestemchemon's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corestemchemon PB Ratio Chart

Corestemchemon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 8.83 7.89 4.31 7.39

Corestemchemon Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 7.39 17.67 14.99 12.09

Competitive Comparison of Corestemchemon's PB Ratio

For the Biotechnology subindustry, Corestemchemon's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corestemchemon's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corestemchemon's PB Ratio distribution charts can be found below:

* The bar in red indicates where Corestemchemon's PB Ratio falls into.



Corestemchemon PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Corestemchemon's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=3590.00/990.948
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Corestemchemon  (XKRX:166480) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Corestemchemon PB Ratio Related Terms

Thank you for viewing the detailed overview of Corestemchemon's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corestemchemon Business Description

Traded in Other Exchanges
N/A
Address
Pangyo 255 beongil 24 I & C Building, 2nd Floor, yeonggi-do, Bundang-gu, Seongnam, Seoul, KOR, 13486
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

Corestemchemon Headlines

No Headlines